Skip to main content

Table 2 Unadjusted measures of abandonment, adherence and persistence according to pharmacy channel

From: Impact of pharmacy channel on adherence to oral oncolytics

Characteristica

Specialty

Traditional Retail

P-value

Number of Patients

11,972

30,394

 

Abandonment of Index Prescription

<0.001

 Approved Without Challenges, N (%)

11,731

98.0%

28,788

94.7%

 

 Initial Challenge but Overcome, N (%)

118

1.0%

875

2.9%

 

 Initial Challenge Unknown if Overcome, N (%)b

3

0.0%

43

0.1%

 

 Abandoned, N (%)c

97

0.8%

604

2.0%

 

 Unknown, N (%)d

23

0.2%

84

0.3%

 

Adherence - Proportion of Days Covered between the First and Last Fille

 

 Mean (SD)

0.86 (0.2)

0.79 (0.2)

<0.001

 Number with >1 fill

9194

22,219

 

 Adherent, N (%)

6586

71.6%

12,542

56.4%

<0.001

Adherence - Proportion Days Covered between First and Last Fill, N (%)

<0.001

 0–0.20

12

0.1%

246

1.1%

 

 0.21–0.40

241

2.6%

1273

5.7%

 

 0.41–0.60

984

10.7%

3815

17.2%

 

 0.61–0.70

733

8.0%

2571

11.6%

 

 0.70–0.79

638

6.9%

1772

8.0%

 

 0.80–0.90

965

10.5%

2182

9.8%

 

 0.90–1.00

5621

61.1%

10,360

46.6%

 

Persistencef,g - Time until Discontinuation of Index Oncolytic (days)

 

 Number Filling Prescription for Index Oncolytic

11,849

29,663

 

 Mean (SD)

186.2 (235.2)

161.8 (218.5)

<0.001

 Median

94

83

 

 Minimum–Maximum

0–1622

0–1613

 
  1. Abbreviations: SD standard deviation, N number of patients
  2. aGroup comparisons were made using 2-sided Pearson chi-square for categorical measures and t-test statistics for continuous measures, P-values are presented for comparisons using traditional retail as reference group
  3. bUnable to determine if hurdle was overcome because follow-up time was censored
  4. cAbandonment measure refers to whether the patient was able to successfully fill prescription within 90 days following an initial challenge (if no, prescription was considered abandoned)
  5. dNo information provided regarding the patient’s first fill status, could not determine if prescription was filled
  6. eAdherence definition excluded patients who only had one prescription fill or abandoned their index prescription (calculation included n = 9194 and n = 22,219 specialty and traditional retail patients, respectively)
  7. fTime until discontinuation (in days) of index oral oncolytic, allowing for a 60-day gap in therapy between the run-out date of the medication and the subsequent fill
  8. gThe definition of persistence excluded patients who abandoned their index oncolytic (calculation included n = 11,849 and n = 29,663 specialty and traditional retail patients, respectively)